Close Menu

NEW YORK – Fluidigm disclosed on Monday that it has finalized a contract with the National Institutes of Health related to the production of its microfluidics-based molecular test for SARS-CoV-2.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.